A radical shift in US pharmaceutical policy
President Donald Trump’s administration has begun an unprecedented chapter in international trade policy by turning its sights toward a historically protected sector: the pharmaceutical industry. After imposing tariffs on products such as steel, aluminum and automobiles, the Republican president has announced his intention to apply tariffs that could reach 200% on imported medicines, breaking with decades of tariff exemptions for these types of products.
This analysis meticulously examines the implications of a measure that represents a paradigmatic shift in the economic and public health strategy of the United States. For more than half a century, pharmaceutical products entered the United States tariff-free, a policy designed to guarantee access to essential medicines. The new proposal disrupts this fundamental principle.
The implementation mechanism and its schedule
U.S. and European leaders recently detailed a trade deal that includes a 15% tariff rate on some European goods, including pharmaceuticals. However, Trump’s threat goes considerably further, promising taxes that multiply that percentage by more than thirteen. According to Maytee Pereira of the tax and consulting firm PwC, these plans generate “shock and amazement” among drug manufacturers, who would go “from zero tariffs to the potential of 200%.”
The president has indicated that he would delay the implementation of these levies between twelve and eighteen months, granting pharmaceutical companies a grace period to accumulate inventories and transfer their manufacturing operations to US territory. David Risinger, an analyst at Leerink Partners, confirmed in a July 29 report that most laboratories have already increased their imports and could maintain between six and 18 months of inventory in the United States.
Economic and public health consequences
Paradoxically, while Trump has promised Americans to reduce their drug costs, analysts anticipate that this measure could have the opposite effect. Diederik Stadig, a health economist at financial services firm ING, warned in a recent analysis that “a tariff would hurt consumers most of all, as they would feel the inflationary effect directly when paying for prescriptions at the pharmacy and indirectly through higher insurance premiums.” Stadig added that low-income households and the elderly would experience the most severe impact.
The analyst estimates that even a 25% tax – substantially lower than proposed – would gradually increase drug prices in the United States by between 10% and 14% as accumulated reserves are depleted. Jefferies analyst David Windley projects in recent research that the full effects of the tariffs, if implemented in the second half of 2026, could extend into 2027 or 2028 precisely because of this inventory buildup.
The geopolitical and national security background
This initiative does not arise in a vacuum. The experience of the COVID-19 pandemic highlighted the strategic risks of relying on globalized supply chains for critical medical products. During the crisis, multiple countries restricted exports of protective equipment and medical supplies, revealing the vulnerability of the United States in this sector.
In April 2024, the administration launched an investigation under Section 232 of the Trade Expansion Act of 1962, which allows the president to impose tariffs on national security grounds, to determine how the importation of drugs and active pharmaceutical ingredients affects the country’s security. Marta Wosinska, a health policy analyst at the Brookings Institution, explains that tariffs can play a role in securing critical medical supplies, citing the example of the Biden administration, which successfully imposed taxes on foreign syringes when cheap imports from China threatened to wipe out domestic producers.
The United States trade deficit in medicinal and pharmaceutical products reached almost 150 billion dollars last year, a figure that reflects the magnitude of external dependence. For decades, pharmaceutical companies moved operations overseas to take advantage of lower costs in countries like China and India, and tax benefits in jurisdictions like Ireland and Switzerland.
Corporate reactions and productive realignment
Faced with this new regulatory reality, pharmaceutical giants have already begun a process of strategic adaptation. The Swiss laboratory Roche announced in April an investment of $50 billion to expand its operations in the United States. Johnson & Johnson, for its part, will dedicate $55 billion within the United States over the next four years. Joaquin Duato, general director of the company, recently indicated that the objective is to supply medicines for the US market completely from facilities located in the country.
Many sector analysts, however, remain skeptical about the final implementation of the measure. They anticipate that the administration could settle for a tariff significantly lower than the announced 200%, and speculate that the policy could include exemptions for critical products such as low-margin generic drugs, which account for approximately 90% of prescriptions dispensed in the United States but only 18% of pharmaceutical spending.
Trump’s proposal thus represents a complex balance between the stated objective of repatriating pharmaceutical manufacturing, strengthening national security and reducing dependence on China – a key geopolitical rival – against the tangible risk of increasing healthcare costs for American consumers and potentially disrupting supply chains for essential medicines.
Has this analysis of the global implications of trade policies in the health sector been revealing to you? Share this article on your social networks to contribute to an informed conversation and explore more content on economics and public policy in our specialized section.
